Log in

NASDAQ:CURNeuralstem Stock Price, Forecast & News

$0.92
-0.03 (-3.16 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.86
Now: $0.92
$0.94
50-Day Range
$0.67
MA: $0.79
$0.93
52-Week Range
$1.10
Now: $0.92
$13.78
Volume1.56 million shs
Average Volume1.98 million shs
Market Capitalization$1.93 million
P/E RatioN/A
Dividend YieldN/A
Beta1.81
Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidate is NSI-189, a chemical entity, which has been completed Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical study for the treatment-refractory depression, Angelman Syndrome, Alzheimer's disease, ischemic stroke, diabetic neuropathy, irradiation-induced cognitive deficit, and long-term potentiation enhancement. The company also develops NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease; Phase II clinical trial for the treatment of chronic ischemic stroke; and Phase I clinical trials for the treatment of chronic spinal cord injury, as well as is in preclinical study for the traumatic brain injury. In addition, it develops NSI-532, which is in preclinical study for treatment of Alzheimer's disease; and NSI-777 that is in preclinical study for treatment of human demyelinating diseases. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
Read More
Neuralstem logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.83 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CUR
CUSIPN/A
Phone301-366-4841

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$260,000.00
Book Value$6.64 per share

Profitability

Net Income$-4,930,000.00
Net Margins-39,417.64%

Miscellaneous

Employees6
Market Cap$1.93 million
Next Earnings DateN/A
OptionableOptionable

Receive CUR News and Ratings via Email

Sign-up to receive the latest news and ratings for CUR and its competitors with MarketBeat's FREE daily newsletter.

Neuralstem (NASDAQ:CUR) Frequently Asked Questions

How has Neuralstem's stock been impacted by COVID-19 (Coronavirus)?

Neuralstem's stock was trading at $0.7516 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CUR shares have increased by 22.4% and is now trading at $0.92. View which stocks have been most impacted by Coronavirus.

How were Neuralstem's earnings last quarter?

Neuralstem, Inc. (NASDAQ:CUR) announced its quarterly earnings data on Wednesday, August, 14th. The company reported ($1.45) earnings per share (EPS) for the quarter. The firm had revenue of $0.01 million for the quarter. Neuralstem had a negative net margin of 39,417.64% and a negative return on equity of 170.51%. View Neuralstem's earnings history.

When did Neuralstem's stock split? How did Neuralstem's stock split work?

Neuralstem's stock reverse split on Thursday, July 18th 2019. The 1-20 reverse split was announced on Tuesday, July 16th 2019. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 17th 2019. An investor that had 100 shares of Neuralstem stock prior to the reverse split would have 5 shares after the split.

Has Neuralstem been receiving favorable news coverage?

News coverage about CUR stock has trended somewhat positive this week, InfoTrie reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Neuralstem earned a daily sentiment score of 1.5 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutNeuralstem.

Who are some of Neuralstem's key competitors?

What other stocks do shareholders of Neuralstem own?

Who are Neuralstem's key executives?

Neuralstem's management team includes the following people:
  • Dr. Kenneth C. Carter, Exec. Chairman, CEO & Principal Financial Officer (Age 59)
  • Dr. Karl Y. Johe, Co-Founder (Age 59)
  • Dr. Thomas G. Hazel Ph.D., Sr. VP of Research
  • Dr. David P. Recker, Chief Medical Officer (Age 61)

What is Neuralstem's stock symbol?

Neuralstem trades on the NASDAQ under the ticker symbol "CUR."

How do I buy shares of Neuralstem?

Shares of CUR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Neuralstem's stock price today?

One share of CUR stock can currently be purchased for approximately $0.92.

How big of a company is Neuralstem?

Neuralstem has a market capitalization of $1.93 million and generates $260,000.00 in revenue each year. Neuralstem employs 6 workers across the globe.

What is Neuralstem's official website?

The official website for Neuralstem is www.neuralstem.com.

How can I contact Neuralstem?

Neuralstem's mailing address is 20271 Goldenrod Lane, Germantown MD, 20876. The company can be reached via phone at 301-366-4841 or via email at [email protected]

This page was last updated on 5/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.